S. Pazhanisamy - Concepedia

Author

S. Pazhanisamy

Vertex Pharmaceuticals (United States)

Also Known As

S Pazhanisamy, S. PAZHANISAMY, S. Pazhanisamy, Sam Pazhanisamy

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Vertex Pharmaceuticals (United States)Wesleyan University

About

S. Pazhanisamy is an author at Vertex Pharmaceuticals (United States) specializing in biochemistry, medicine, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Biochemistry	10	10	566
2	Medicine	9	9	549
3	Natural Sciences	8	8	519
4	Cell Biology	2	2	123
5	Engineering	1	1	17

S. Pazhanisamy

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase Keith P. Wilson, Patricia G. McCaffrey, Kathy Hsiao, Chemistry & Biology Drug TargetP38 Map KinaseBiochemistryPyridinylimidazole InhibitorsMedicine	1997	275
In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease Judith A. Partaledis, Koushi Yamaguchi, Margaret Tisdale, Journal of Virology	1995	186
A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase Ted Fox, Joyce T. Coll, Xiaoling Xie, Protein Science	1998	135
In Vitro and In Vivo Isotope Effects with Hepatitis C Protease Inhibitors: Enhanced Plasma Exposure of Deuterated Telaprevir versus Telaprevir in Rats François Maltais, Young Chun Jung, Minzhang Chen, Journal of Medicinal Chemistry	2009	97
The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor John P. Duffy, Edmund Harrington, Francesco G. Salituro, ACS Medicinal Chemistry Letters	2011	82
Kinetic Characterization of Human Immunodeficiency Virus Type-1 Protease-resistant Variants S. Pazhanisamy, Cameron M. Stuver, Aine B. Cullinan, Journal of Biological Chemistry	1996	77
Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Human Immunodeficiency Virus Therapy D. J. Livingston, S. Pazhanisamy, David Porter, The Journal of Infectious Diseases ImmunologyMolecular BiologyAntiviral DrugImmunotherapyHuman Retrovirus	1995	69
Kinetic Mechanism of the p38-α MAP Kinase: Phosphoryl Transfer to Synthetic Peptides Guanjing Chen, Margaret Porter, John R. Bristol, Biochemistry Molecular BiologySynthetic PeptidesPeptide ScienceKinetic MechanismMolecular Pharmacology	2000	54
Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors Jingrong Cao, Huai Gao, Guy W. Bemis, Bioorganic & Medicinal Chemistry Letters Combinatorial ChemistryMedicinal ChemistryBiochemistryNatural SciencesMedicine	2009	45
Design and synthesis of novel conformationally restricted HIV protease inhibitors Francesco G. Salituro, Christopher Baker, John J. Court, Bioorganic & Medicinal Chemistry Letters Combinatorial ChemistryBiochemistryMedicineHiv Protease InhibitorsAntiviral Drug Development	1998	37

Page 1